Advertisement

Advertisement

Colorectal Cancer

Time to Treatment and Survival Among Adults Aged

In a Canadian retrospective cohort study reported in JAMA Network Open, Castelo et al found that a greater interval between date of presentation and treatment initiation was not associated with an increased risk of poorer survival among patients with colorectal cancer diagnosed before age 50. The...

Colorectal Cancer

Avelumab vs Standard Second-Line Chemotherapy in dMMR/MSI Metastatic Colorectal Cancer

In the French phase II SAMCO-PRODIGE 54 trial reported in JAMA Oncology, Julien Taïeb, MD, PhD, and colleagues found that second-line avelumab improved progression-free survival vs standard chemotherapy in patients with mismatch repair­–deficient and/or microsatellite instability (dMMR/MSI)...

Colorectal Cancer

PANDA Trial: First-Line Treatment Regimens for Elderly Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer

In the Italian phase II noncomparative PANDA trial reported in the Journal of Clinical Oncology, Lonardi et al found that regimens adding panitumumab to modified FOLFOX (fluorouracil, leucovorin, and oxaliplatin; mFOLFOX) and to fluorouracil/leucovorin were active in the first-line treatment of...

Colorectal Cancer

Report Highlights Rapid Adoption of Clinical Research Results Into Colon Cancer Chemotherapy Prescribing Patterns

New research published by Ou et al in JNCCN—Journal of the National Comprehensive Cancer Network evaluated how an important analysis on adjuvant chemotherapy for advanced colon cancer impacted prescribing patterns. The IDEA collaboration included more than 12,000 patients with stage III colon...

Colorectal Cancer
Gynecologic Cancers
Issues in Oncology

Comparison of Outcomes of Surgical vs Nonsurgical Approaches in Patients With Malignant Bowel Obstructions

Researchers have compared the efficacy of surgical and nonsurgical interventions for patients with malignant bowel obstructions, according to a recent study published by Krouse et al in The Lancet Gastroenterology & Hepatology. The new findings may help to inform clinical decision-making in the ...

Colorectal Cancer
Issues in Oncology

ACP Issues Updated Clinical Guidelines for Screening Asymptomatic, Average-Risk Adults for Colorectal Cancer

The American College of Physicians (ACP) suggested screening asymptomatic, average-risk adults for colorectal cancer at age 50 years, according to updated clinical guidelines published by Qaseem et al in the Annals of Internal Medicine. New ACP Clinical Guidelines Colorectal cancer has the fourth...

Colorectal Cancer

FDA Approves Trifluridine and Tipiracil With Bevacizumab for Previously Treated Metastatic Colorectal Cancer

On August 2, the U.S. Food and Drug Administration (FDA) approved trifluridine and tipiracil (Lonsurf) with bevacizumab for patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and, if ...

Colorectal Cancer
Survivorship
Geriatric Oncology

Gastrointestinal Symptoms May Be Prevalent in Geriatric Female Colorectal Cancer Survivors

About 80% of geriatric female colorectal cancer survivors may experience a range of gastrointestinal symptoms years after receiving a diagnosis and treatment for their tumors, according to a recent study published by Han et al in PLOS ONE. Background While depression, anxiety, and fatigue are...

Colorectal Cancer
Issues in Oncology

Patients in Lower-Income Communities May Be Less Likely to Receive CT Colonography Than Those in Higher-Income Communities

Patients who reside in lower-income communities may be less likely to undergo colorectal cancer screenings with computed tomography (CT) colonography than those who reside in higher-income communities, according to a new study published by Christensen et al in the American Journal of ...

Colorectal Cancer

Reasons for Nonparticipation in a Colorectal Cancer Screening Trial Comparing Outcomes With Colonoscopy vs FIT

In an analysis reported in JAMA Network Open, Robertson et al found U.S. veterans most frequently cited a preference for stool testing as a reason for declining participation in the CONFIRM trial, which compared the effect on colorectal cancer mortality with annual colonoscopy vs annual fecal...

Colorectal Cancer

Modeled Effects of Reducing the Recommended Screening Age for Colorectal Cancer in Canada

In a modeling study reported in JAMA Oncology, Kalyta et al found that reducing the starting age for colorectal cancer screening with the biennial fecal immunochemical test (FIT) in Canada would result in reduction in colorectal cancer burden at a “modest cost.” As stated by the investigators:...

Survivorship
Colorectal Cancer
Breast Cancer
Prostate Cancer

Primary Cancer and Noncancer Mortality Among Long-Term Survivors of Solid Tumors

In a study reported in JAMA Network Open, KC et al identified factors involved with primary cancer mortality vs noncancer mortality among long-term survivors of breast, prostate, and colorectal cancers. Study Details The study included data on 627,702 patients in the Surveillance, Epidemiology,...

Colorectal Cancer

Integrated Clinical-Molecular Classification of Colorectal Liver Metastases

In a study reported in JAMA Oncology, Katipally et al found that an integrated clinical-molecular classification of colorectal cancer metastases to the liver distinguished risk groups for survival outcomes. Study Details The investigators had previously defined three biologically distinct molecular ...

Colorectal Cancer
Gynecologic Cancers

MLH1 Methylation Status and Screenings for Colorectal or Endometrial Cancer

New research could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, according to a novel study published by Hitchins et al in JNCCN–Journal of the National Comprehensive Cancer Network. The findings suggest that the guidelines leave a...

Colorectal Cancer
Geriatric Oncology

Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery

In a study of real-world prospective data—GOSAFE—reported in the Journal of Clinical Oncology, Montroni et al found that the majority of patients aged ≥ 70 years undergoing colorectal cancer surgery showed maintained or improved quality of life and achieved functional recovery during follow-up....

Colorectal Cancer
Genomics/Genetics

Germline Variants in Colorectal Cancer Susceptibility Genes by Race/Ethnicity in Patients With Early-Onset Colorectal Cancer

In a study reported in the Journal of Clinical Oncology, Seagle et al identified the prevalence of germline colorectal cancer susceptibility gene variants according to race and ethnicity among patients with early-onset colorectal cancer. Study Details The study involved patients aged 15 to 49 years ...

Colorectal Cancer

PROSPECT Trial: Pelvic Radiation Therapy Avoided for Most Patients With Intermediate-Risk, Locally Advanced Rectal Cancer

Patients with intermediate-risk rectal cancer who received neoadjuvant chemotherapy with selective use of pelvic chemoradiation therapy had disease-free survival that was noninferior to the standard approach using pelvic chemoradiation, according to findings from the randomized phase III PROSPECT...

Colorectal Cancer

Association of Alcohol Intake With Risk of Early-Onset Colorectal Cancer

In a Korean study reported in the Journal of Clinical Oncology, Jin et al found that increased alcohol intake may be associated with an increased risk of early-onset colorectal cancer. Study Details The study involved data from 5,666,576 individuals aged 20 to 49 years from the Korean National...

Colorectal Cancer

First-Line FOLFOXIRI Plus Cetuximab or Bevacizumab in BRAF V600E–Mutant Metastatic Colorectal Cancer

In the German phase II FIRE-4.5 trial reported in the Journal of Clinical Oncology, Stintzing et al found that the addition of cetuximab vs bevacizumab to FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) did not improve objective response rate in the first-line treatment of...

Colorectal Cancer

First-Line Systemic Treatment Strategies for Initially Unresectable Colorectal Cancer Liver Metastases

In the Dutch Colorectal Cancer Group phase III CAIRO5 study reported in The Lancet Oncology, Bond et al investigated first-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases. The researchers found that FOLFOXIRI (leucovorin, fluorouracil,...

Colorectal Cancer
Issues in Oncology

Study Identifies Potential Risk Factors for Early-Onset Colorectal Cancer in Male Patients

Researchers have identified seven potential risk factors for early-onset colorectal cancer in male patients and developed a novel risk evaluation model, according to a recent study published by Imperiale et al in Cancer Prevention Research. The findings may help 45- to 49-year-old patients accept...

Colorectal Cancer

Use of Fruquintinib in Treating Refractory Metastatic Colorectal Cancer

In the phase III FRESCO-2 trial reported in The Lancet, Dasari et al found that the VEGFR-1,2,3 inhibitor fruquintinib prolonged survival vs placebo in patients with refractory metastatic colorectal cancer. Study Details In the double-blind trial, 691 patients from sites in 14 countries were...

Colorectal Cancer

Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer

A report from the German OCUM study published by Ruppert et al in the Journal of Clinical Oncology details long-term locoregional recurrence outcomes with risk-adapted neoadjuvant chemoradiotherapy plus total mesorectal excision and total mesorectal excision alone in patients with rectal cancer....

Colorectal Cancer
Genomics/Genetics

Expert Point of View: Lisa Newman, MD, MPH, FACS, FASCO

Commenting on this study on clinical genomic profiling for colorectal cancer, Lisa Newman, MD, MPH, FACS, FASCO, Chief of the Section of Breast Surgery and leader of the Multidisciplinary Breast Oncology Programs at Weill Cornell Medicine and NewYork-Presbyterian, commended the authors for...

Colorectal Cancer
Genomics/Genetics

Retrospective Study Finds Black Patients With Colorectal Cancer Had Fewer Actionable Genomic Mutations Than White Patients

Black individuals have a higher incidence of colorectal cancer than White individuals, and their outcomes are worse. Undoubtedly, reasons for this are multifaceted, but the disparity in outcomes may be partly explained by genomic differences, documented in a large retrospective study presented at...

Colorectal Cancer
Genomics/Genetics

Effect of Upregulated KDM5D Gene on Y Chromosome in Male Patients With KRAS-Mutated Colorectal Cancer

Researchers have revealed that the KDM5D gene on the Y chromosome, which is upregulated in KRAS-mutated colorectal cancer, may be responsible for increasing tumor cell invasiveness and reducing antitumor immunity in male patients, according to a recent study published by Li et al in Nature. The new ...

Colorectal Cancer

Patients With Refractory Metastatic Colorectal Cancer May Experience Survival Benefits With Fruquintinib

Targeted therapy with fruquintinib may improve overall survival and progression-free survival  in patients with refractory metastatic colorectal cancer, according to a novel study published by Dasari et al in The Lancet. Background According to the American Cancer Society, colorectal cancer is the...

Colorectal Cancer

Patient-Reported Outcomes From the PROSPECT Trial: Neoadjuvant FOLFOX vs Chemoradiation for Locally Advanced Rectal Cancer

In an analysis from the PROSPECT trial (Alliance N1048) reported in the Journal of Clinical Oncology, Ethan Basch, MD, MSc, FASCO, and colleagues identified patient-reported outcome patterns among those receiving neoadjuvant FOLFOX (fluorouracil, leucovorin, oxaliplatin) or pelvic chemoradiation...

Colorectal Cancer

Longitudinal ctDNA Methylation Status and Risk of Recurrence After Surgery in Patients With Stage I to III Colorectal Cancer

In a Chinese study reported in JAMA Oncology, Mo et al found that longitudinal measurement of circulating tumor DNA (ctDNA) methylation permitted early detection of disease recurrence in patients undergoing surgery for stage I to III colorectal cancer.  Study Details In the prospective cohort...

Breast Cancer
Colorectal Cancer
Gynecologic Cancers
Issues in Oncology

Impact of Historic Redlining Practices on Cancer Screening Rates

Although redlining was outlawed more than 50 years ago, individuals who currently live in historically redlined areas may be less likely to be screened for breast cancer, colorectal cancer, and cervical cancer than individuals who live in areas not associated with redlining practices, according to...

colorectal cancer

Cathy Eng, MD, and Thejus Jayakrishnan, MD, on Colorectal Cancer: Metabolomic Differences in Young-Onset vs Average-Onset Disease

Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, and Thejus Jayakrishnan, MD, of the Cleveland Clinic Taussig Cancer Institute, discuss significant differences in the citrate cycle, a core pathway of cellular metabolism associated with colorectal cancer. Metabolomic differences impacted by environmental exposures (arginine biosynthesis and dietary red meat) were also noted, suggesting possible links with younger age of onset in this disease (Abstract 3510).

colorectal cancer

Smitha Krishnamurthi, MD, and Deb Schrag, MD, MPH, on Rectal Cancer: New Findings on Chemoradiation, Chemotherapy, and Excision

Smitha Krishnamurthi, MD, of the Cleveland Clinic, and Deb Schrag, MD, MPH, of Memorial Sloan Kettering Cancer Center, discuss phase III findings from the PROSPECT trial, which showed FOLFOX chemotherapy with selective use of radiation therapy and sensitizing fluoropyrimidine (5FUCRT) is noninferior to 5FUCRT for the neoadjuvant treatment of patients with locally advanced rectal cancer, prior to low anterior resection with total mesorectal excision (Abstract LBA2).

colorectal cancer

Cathy Eng, MD, and Lars Henrik Jensen, MD, PhD, on Locally Advanced Colon Cancer: Efficacy of Neoadjuvant Chemotherapy and Standard Treatment

Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, and Lars Henrik Jensen, MD, PhD, of the Danish Colorectal Cancer Center South and the University Hospital of Southern Denmark, discuss phase III results from the Scandinavian NeoCol trial, which showed that neoadjuvant chemotherapy is not superior to standard upfront surgery in terms of disease-free and overall survival in patients with colon cancer, although there are certain circumstances when this approach may have more favorable outcomes (Abstract LBA3503).

Colorectal Cancer

Transcriptional Profiling May Provide Clues to Treating Colorectal Cancer More Effectively in Younger Patients

A novel study is shedding light on factors that may affect treatment response in patients with young-onset colorectal cancer. Researchers uncovered differences in transcriptional metabolic profiles and other drivers of disease, as well as immune profiles, between younger and older patients with...

Colorectal Cancer

Radiation May Be Safely Omitted in Select Patients With Locally Advanced Rectal Cancer

Patients with locally advanced rectal cancer with tumors that respond to chemotherapy may safely forgo radiation therapy before surgery, based on the findings of the PROSPECT trial. These data were presented by Deborah Schrag, MD, FASCO, MPH, at the 2023 ASCO Annual Meeting (Abstract LBA2) and...

colorectal cancer

Thierry Conroy, MD, on Rectal Cancer: Long-Term Results on mFOLFIRINOX vs Preoperative Chemoradiation Therapy

Thierry Conroy, MD, of the Institut de Cancérologie de Lorraine, discusses phase III findings from the PRODIGE 23 trial, showing that neoadjuvant chemotherapy with mFOLFIRINOX followed by chemoradiotherapy, surgery, and adjuvant chemotherapy improved all outcomes, including overall survival, in patients with locally advanced rectal cancer compared with standard chemoradiotherapy, surgery, and adjuvant chemotherapy (Abstract LBA3504).

colorectal cancer

Sebastian Stintzing, MD, on Colorectal Cancer: Influence of Liquid Biopsy in First-Line Combination Treatment

Sebastian Stintzing, MD, of the Charité Universitätsmedizin Berlin, discusses results from the phase III FIRE-4 study, which showed that liquid biopsy is clinically relevant in verifying mutational status in patients with metastatic colorectal cancer and is efficacious in first-line treatment of FOLFIRI and cetuximab for patients with RAS wild-type disease (Abstract 3507).

Colorectal Cancer

Study Finds Wide Variations in Intratumoral Microbiome of Patients With Early- vs Late-Onset Colorectal Cancer

Researchers have found that the bacteria, fungi, and viruses within the tumors of patients with colorectal cancer varied significantly depending on whether they were diagnosed with early-onset or late-onset disease, according to new findings presented by Weinberg et al at the 2023 ASCO Annual...

Colorectal Cancer
Lung Cancer
Breast Cancer
COVID-19

Incidence of Colorectal, Lung, and Breast Cancers May Be Rising Due to COVID-19–Related Screening Delays

Delays in cancer screenings during the COVID-19 pandemic may have resulted in lower reported incidences of colorectal, lung, and breast cancers, reflecting potentially high rates of undiagnosed cancer and later-stage diagnoses, according to a new study published by Romatoski et al in the Journal of ...

Colorectal Cancer
Genomics/Genetics
Immunotherapy

Addition of Panitumumab to Trifluridine/Tipiracil in Anti-EGFR Treatment Rechallenge in Refractory RAS Wild-Type Metastatic Colorectal Cancer

In the Italian phase II VELO trial reported in JAMA Oncology, Napolitano et al found that anti-EGFR treatment rechallenge with the addition of panitumumab to trifluridine/tipiracil improved progression-free survival in the third-line setting for patients with RAS wild-type metastatic colorectal...

Gastrointestinal Cancer
Colorectal Cancer
Issues in Oncology

Association Between Overweight/Obesity and Risk of Gastrointestinal Cancer

Researchers have found that individuals in early and middle adulthood who have a body mass index (BMI) indicating that they have overweight or obesity may be at an increased risk of developing gastrointestinal cancer, according to a new study published by Loomans-Kropp and Umar in JAMA Network...

Colorectal Cancer
Immunotherapy

Addition of Bevacizumab to Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer

As reported in The New England Journal of Medicine by Prager et al, the phase III SUNLIGHT trial has shown prolonged overall survival with the addition of bevacizumab to trifluridine/tipiracil (FTD-TPI) in previously treated patients with metastatic colorectal cancer. As stated by the...

Breast Cancer
Colorectal Cancer
Prostate Cancer
Genomics/Genetics

Potential Utility of Polygenic Risk Scores in Cancer Screening in the United Kingdom

In a modeling study reported in The Lancet Oncology, Huntley et al found that the extension of UK cancer screening programs for breast, prostate, and colorectal cancers to a polygenic risk score (PRS)-defined high-risk group of patients with cancer may improve cancer case detection and avoidance of ...

Colorectal Cancer

Tucatinib Plus Trastuzumab in HER2-Positive, Refractory, RAS Wild-Type, Unresectable or Metastatic Colorectal Cancer

As reported in The Lancet Oncology by John H. Strickler, MD, and colleagues, the phase II MOUNTAINEER trial has shown the activity of the combination of tucatinib plus trastuzumab in patients with HER2-positive, chemotherapy-refractory, RAS wild-type, unresectable or metastatic colorectal cancer....

Hepatobiliary Cancer
Colorectal Cancer
Issues in Oncology

Three New Studies Unveil Recent Developments in the Screening and Treatment of Biliary Tract Cancer and Colorectal Cancer

Researchers have revealed the impacts of several new developments in screening and treating patients with biliary tract cancer and colorectal cancer—including the development of patient-derived organoids to test chemotherapy response, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to...

Colorectal Cancer

Birth by Cesarean Delivery and Development of Early-Onset Colorectal Cancer

In a Swedish study reported in JAMA Network Open, Cao et al found that females born via cesarean delivery were at an increased risk of early-onset colorectal cancer vs those born via vaginal delivery. No increased risk was observed among males born via cesarean delivery. As noted by the...

Gastroesophageal Cancer
Gastrointestinal Cancer
Pancreatic Cancer
Colorectal Cancer
Hepatobiliary Cancer

Risk of Early-Onset Digestive Tract Cancers Among Young Adults With Nonalcoholic Fatty Liver Disease

In a Korean nationwide cohort study reported in the Journal of Clinical Oncology, Park et al found that individuals aged 20 to 39 years with nonalcoholic fatty liver disease (NAFLD) were at an increased risk of developing early-onset digestive tract cancers. Study Details The study included data on ...

Colorectal Cancer
Issues in Oncology

Newly Identified Risk Factors May Point to a Heightened Risk for Early-Onset Colorectal Cancer Among Younger Adult Patients

Researchers have identified four warning signs and symptoms that may indicate an elevated risk of early-onset colorectal cancer, according to a new study published by Fritz et al in the Journal of the National Cancer Institute. The findings may be key to helping physicians more effectively detect...

COVID-19
Breast Cancer
Colorectal Cancer

Lifestyle Habits, Risk Factors, and Cancer Screening During COVID-19 Pandemic

Investigators discovered both favorable and unfavorable changes in major cancer risk factors, preventive behaviors and services, and screenings in the United States during the COVID-19 pandemic, according to a new study published by Star et al in Cancer Epidemiology, Biomarkers & Prevention....

supportive care
symptom management
breast cancer
colorectal cancer

Lindsay L. Peterson, MD, on Exercise and Cancer Outcomes

Lindsay L. Peterson, MD, of the Washington University, St. Louis, discusses the value of physical activity in improving cancer prognosis, especially for patients with breast or colon cancer. Aerobic exercises and resistance training are recommended during and after treatment. Exercise may help inhibit tumor growth, improve quality of life by decreasing fatigue and anxiety, build muscle mass, increase physical function, and reduce surgical complications and treatment delays.

Advertisement

Advertisement

Advertisement